Chinese Journal of Integrative Medicine最新文献

{"title":"Antidepressant and Anxiolytic Effects of Intranasal Curcumin in Parkinson's Disease Model Rats: Inhibition of Neuroinflammation and Oxidative Stress.","authors":"Rui-Fang She, Qian Zhang, Fang-Fang Zhao, Kun Yang, Qian Chen, Yi-Feng Yang, Hong-Jun Li, Xiao-Hong Li, Xiang-Ting Li","doi":"10.1007/s11655-026-3937-y","DOIUrl":"https://doi.org/10.1007/s11655-026-3937-y","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the potential of intranasal curcumin (IN-CUCM) administration in alleviating anxio-depressive disorders in a rotenone (Rot)-induced Parkinson's disease (PD) rat model.</p><p><strong>Methods: </strong>Adult male Wistar rats were administered Rot [3 mg/(kg·d)] for 14 d to induce PD and subsequently treated with IN-CUCM [2.5, 5, or 10 mg/(kg·d)] or fluoxetine [FLU, 10 mg/(kg·d)] for an additional 14 d (n=14 per group). Behavioral tests, including open field test, forced swimming test, and tail suspension test, were conducted to evaluate depression- and anxiety-like symptoms. The hippocampal (HPC) and prefrontal cortical (PFC) samples were analyzed for antioxidant enzymes (glutathione, catalase, and superoxide dismutase), oxidative stress (OS) markers (malondialdehyde and nitrite), and inflammatory mediators [nuclear factor kappa B (NF-κB), NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), caspase-1 (Casp-1), apoptosis-associated specklike protein (ASC), and cytokines] using enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, respectively. Molecular docking verification was also conducted.</p><p><strong>Results: </strong>IN-CUCM [5 and 10 mg/(kg·d)] significantly ameliorated anxio-depressive-like behaviors of PD rats induced by Rot, and regulated OS biomarkers and endogenous antioxidants in both HPC and PFC (P<0.01). Additionally, IN-CUCM attenuated neuroinflammatory responses by downregulating NF-κB, ASC, NLRP3, and Casp-1, and modulating cytokines in these brain regions (P<0.01). Molecular docking analysis revealed a high affinity of CUCM for the NF-κB/NLRP3 inflammasome pathway.</p><p><strong>Conclusion: </strong>IN-CUCM effectively alleviates anxio-depressive-like behaviors in PD by mitigating OS and neuroinflammation.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-pharmaceutical Chinese Medical Therapies for Nausea and Vomiting of Pregnancy: An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Controlled Trials.","authors":"Yi-Xuan Xie, Ya-Nan Sun, Chang-He Yu","doi":"10.1007/s11655-026-4243-4","DOIUrl":"https://doi.org/10.1007/s11655-026-4243-4","url":null,"abstract":"<p><strong>Background: </strong>Nausea and vomiting of pregnancy (NVP) are common symptoms during early pregnancy that significantly impact maternal quality of life and fetal development. Given concerns about the safety of pharmacological treatments, non-pharmaceutical Chinese medical therapies (NPCT) have been new topics of great interest due to their minimal side effects.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of NPCT for the management of NVP through an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.</p><p><strong>Methods: </strong>Eligible data were retrieved from online databases up to August 31, 2024 for subsequent analyses. The quality of included reviews and the certainty of evidence were evaluated using the AMSTAR-2 tool and the GRADE criteria, respectively. Subgroup analyses were performed based on intervention types, treatment methods, and control conditions to explore potential sources of heterogeneity. Primary outcomes included the severity of NVP, treatment effectiveness, and safety.</p><p><strong>Results: </strong>This study included a total of 22 systematic reviews or meta-analyses on various NPCT interventions. The AMSTAR-2 assessment rated 6 studies as high quality, 2 as moderate, and 14 as low or very low quality. The GRADE evaluation categorized evidence as moderate for 5 comparisons, low for 15, and very low for 5 out of the 25 outcome measures. Further analyses revealed the superior effects of acupuncture in decreasing the Pregnancy-Unique Quantification of Emesis score (MD, -1.32; 95% CI, -1.69 to -0.95; moderate evidence), increasing the rate of negative urinary ketone bodies (RR, 1.32; 95% CI, 1.14 to 1.53; moderate evidence); as well as reducing anxiety (MD, 0.78; 95% CI, -1.13 to 2.6; moderate evidence) and depression scores (MD, 0.20; 95% CI, -2.05 to 2.46; moderate evidence).</p><p><strong>Conclusions: </strong>NPCT, particularly acupuncture, may have potential benefits in alleviating NVP. However, due to limited overall quality and certainty of evidence, studies with more rigorous designs and larger sample sizes should be included to produce higher-quality evidence, thereby better informing clinical practice. (PROSPERO registration No. CRD42024590714).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berberine Ameliorates Atherosclerosis by Promoting Mitochondrial Biogenesis via SIRT1/PGC-1α Signaling Pathway.","authors":"Si-Yu Wang, Jun-Meng Zheng, Xin-Yi Han, Bo-Yuan Jin, Cheng-Jun Hua, Yu-Shan Chen, Ting-Ting Wang, Yun-Hao Wang","doi":"10.1007/s11655-026-4037-8","DOIUrl":"https://doi.org/10.1007/s11655-026-4037-8","url":null,"abstract":"<p><strong>Objective: </strong>To investigate berberine (BBR) promotes mitochondrial biogenesis via the silent mating type information regulation 2 homolog 1/peroxisome proliferator-activated receptor gamma coactivator 1 alpha (SIRT1/PGC-1α) signaling pathway to exert its anti-atherosclerosis effects.</p><p><strong>Methods: </strong>A total of 42 8-week-old AopE^-/- mice were fed a high-fat diet for 12 weeks, and then randomly divided into 7 groups via a simple randomization method: the model group, the low-, medium- and high-dose BBR groups [BBRL 50 mg/(kg·d), BBRM 100 mg/(kg·d) and BBRH 150 mg/(kg·d), respectively], positive control group [atorvastatin, 3 mg/(kg·d)], BBR combined with nuclear respiratory factor 1 (Nrf1) inhibitor group (BBRH+EX527, 150 mg/kg BBR+10 mg/kg EX527), and Nrf1 inhibitor group [EX527, 10 mg/(kg·d)]. Six C57BL/6J mice fed with a normal diet were served as control. After 4 weeks of intragastric administration, samples were harvested, and serum, aorta, heart, and liver tissues were isolated for subsequent experiments. Biochemical kits were used to detect serum lipid content in mice. Hematoxylin-eosin, Oil Red O and Masson staining were used to assess lesion severity, lipid deposition, and fibrous cap thickness. Transmission electron microscopy and immunofluorescence were used to analyze mitochondrial morphology and function. Real time quantitative PCR assay and Western blot were utilized to measure the expression levels of SIRT1, PGC-1α, Nrf1, and mitochondrial transcription factor A (TFAM) at both the mRNA and protein levels, along with the quantification of mitochondrial DNA (mtDNA) copy-number in mouse aortas.</p><p><strong>Results: </strong>After BBR intervention, BBRM and BBRH groups significantly reduced blood lipid levels in mice (P<0.01), alleviated aortic plaque deposition, and improved mitochondrial damage (P<0.05 or P<0.01). Additionally, BBR significantly upregulated the mRNA and protein expressions of SIRT1, PGC-1α, Nrf1, and TFAM (P<0.05 or P<0.01). And the relative copy number of mtDNA increased in a dose-dependent manner (P<0.01). In the BBRH+EX527 group, aortic lesions and mitochondrial damage were exacerbated, with concurrent decreases in mRNA and protein expression levels (P<0.05 or P<0.01).</p><p><strong>Conclusion: </strong>BBR promotes mitochondrial biogenesis, maintains mitochondrial function, and inhibits mitochondrial damage through the SIRT1/PGC-1α signaling pathway, thereby improving atherosclerosis.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"System Pharmacology-Based Anti-proliferation and Anti-angiogenesis Mechanisms of Oridonin in Psoriasis Keratinocytes by Blocking PI3K/AKT Signaling Pathway.","authors":"Yang Yang, Su-Wei Tang, Xin-Xin Wu, Wen-Cheng Jiang, Qi-Long Chen","doi":"10.1007/s11655-026-4242-5","DOIUrl":"https://doi.org/10.1007/s11655-026-4242-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To study the anti-proliferative and anti-angiogenic mechanism of oridonin in psoriatic keratinocytes by blocking phosphatidylinositol 3-kinase (PI3K/Akt) signaling pathway based on system pharmacology.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Protein targets of oridonin and psoriasis-related genes were predicted and their overlap was determined using the Venny package in R. The DAVID database was used for enrichment analysis. The oridonin-psoriasis-target and oridonin-target-pathway (OTP) networks associated with psoriasis, as well as a protein-protein interaction, were constructed using Cytoscape. Molecular docking with AutoDock was used to verify the relationships between oridonin and core targets, and ZDOCK was used to assess interactions between core proteins. All bioinformatics results were verified empirically. The mRNA levels of core targets in oridonin-treated cells were measured using real-time q-PCR. The HaCaT keratinocytes were divided to 4 groups: control, low-, medium- and high-concentration groups and treated with different concentrations of oridonin (1, 5 and 10 µmol/L) for 18 h, and then stimulated with tumor necrosis factor (TNF)-α (20 ng/mL) for 6 h. Western blot was used to detect PI3K/Akt pathway protein levels.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Seventy-three targets were found to be strongly associated with the effects of oridonin on psoriasis. The Cluster ONE algorithm was used to extract 6 kernel clusters from the PPI network, and 9 PPI interaction pairs comprising 13 targets showed combined scores ⩾0.999. The OTP network, molecular docking, and protein interaction simulations indicated that oridonin targeted Sirtuin 1 (SIRT1), cyclin dependent kinase 2 (CDK2), Src tyrosine protein kinase (SRC), proteintyrosine phosphatase, nonreceptor-type (PTPN), and SIRT1-tumor protein p53 (TP53), with the CDK2-TP53, SRC-heat shock protein 90 alpha family class a member 1 (HSP90AA1), and PTPN1-epidermal growth factor receptor (EGFR) interaction pairs regulating the PI3K-Akt signaling pathway. Oridonin was observed to block hyperplasia in HaCaT keratinocytes, accompanied by reduced levels of TNF-α, interleukin (IL-)-6, and IL-1 β (P&lt;0.05 or P&lt;0.01). qPCR measurements showed that oridonin significantly inhibited the expression of angiogenesis-related genes, including C-X-C chemokine receptor type 7, C-X-C motif chemokine ligand 12, and vascular endothelial growth factor (P&lt;0.05 or P&lt;0.01). In addition, the qPCR results showed significant changes in the mRNA levels of SIRT1, CDK2, SRC, PTPN1, TP53, HSP90AA1, and EGFR, and Western blot indicated marked changes in the protein levels of cleaved caspase-3, BAD, Bcl-2, p-ERK1/2, and p-p38 after oridonin treatment (P&lt;0.05 or P&lt;0.01).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The study identified the primary oridonin targets during psoriasis treatment using network pharmacology. Bioinformatics analysis with empirical verification demonstrated strong associations between SIRT1, CDK2, ","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Advances in Material Basis for Co-treatment of Cardiovascular and Gastrointestinal Disorders.","authors":"Tao Zhou, Hui-Zhen Tang, Shen-Jun Wang, Yang-Yang Liu, Jun-Zhen Tan, Shuai Zhang, Yi Guo","doi":"10.1007/s11655-026-4032-0","DOIUrl":"https://doi.org/10.1007/s11655-026-4032-0","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Yinhua Miyanling Tablets for Uncomplicated Urinary Tract Infections: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Non-inferiority Clinical Trial.","authors":"Zhen Du, Yi-Wen Tang, Lu-Dong Qiao, Liang Cui, Hui-Ling Wu, Jin-Qiang Yang, Feng Liu, Zhuo Yin, Jian Zhang, Tie-Jun Pan, Shan Chen, Zhan Gao","doi":"10.1007/s11655-026-4154-4","DOIUrl":"https://doi.org/10.1007/s11655-026-4154-4","url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy and safety of Yinhua Miyanling Tablets (YMT) versus levofloxacin in the treatment of female patients with uncomplicated urinary tract infections (uUTIs).</p><p><strong>Methods: </strong>A multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical trial was conducted from August 2022 to August 2023 in 9 tertiary hospitals across China. By using a block randomization method, 480 female patients with uUTI were randomized in a 1:1 ratio to receive either YMT 2 g, 4 times daily for 7 consecutive days (plus levofloxacin-matching placebo) or levofloxacin tablets 0.5 g, once daily for 3 consecutive days (plus YMT-matching placebo). The primary outcome was the proportion of patients requiring additional antimicrobial therapy for uUTIs between day 1 and days 38-42 of treatment, while the secondary outcomes included the Acute Cystitis Symptom Score (ACSS) and urinalysis after 42-d treatment. Safety assessments were conducted based on all adverse events (AEs) and abnormal laboratory test results.</p><p><strong>Results: </strong>A total of 458 women with uUTIs were enrolled in the modified intention-to-treat analysis. Between day 1 and days 38-42 of treatment, the proportion of patients requiring additional antimicrobial therapy was 20.8% (47/226) in the YMT group and 9.9% (23/232) in the levofloxacin group (P<0.01). The non-inferiority criterion (margin 8 = 20%) was met. YMT treatment improved ACSS typical symptoms and quality-of-life scores and urinalysis results compared with levofloxacin, although the differences between groups were not statistically significant (P>0.05). The incidence of treatment-emergent AEs was 7.7% (17/226) in the YMT group and 7.0% (16/232) in the levofloxacin group (P=0.775).</p><p><strong>Conclusions: </strong>YMT is non-inferior to levofloxacin in the proportion of patients requiring additional antimicrobial therapy during treatment of uUTIs in women. YMT treatment is as effective as levofloxacin in terms of improving uUTI symptoms and quality-of-life scores. YMT may be used as a promising adjunctive therapy for uUTIs in women. (Trial registration No. ChiCTR2200066312).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beneficial Herb-Drug Interaction of Shenqi Oral Liquid on Atorvastatin: A Pharmacokinetic and Pharmacodynamic Investigation in Rats with Hyperlipidemia.","authors":"Xian-Run Hu, Man-Lin Li, Wen-Kang Liu, Si-Tong Zhang, Jin-Chun Lei, Jun-Yi Wang, Mi-Re-Yi Bahatijiang, Xue-Mei Cheng, Chang-Hong Wang","doi":"10.1007/s11655-026-4031-1","DOIUrl":"https://doi.org/10.1007/s11655-026-4031-1","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the pharmacodynamic and pharmacokinetic interactions between Shenqi Oral Liquid (SQ) and atorvastatin (ATV) in hyperlipidemic rats, explore the impact of SQ on ATV-related transporters and metabolic enzymes, the potential implications for the safety and rationality of their combined administration based on pharmacodynamic, pharmacokinetic, transporter, and metabolic enzyme data.</p><p><strong>Methods: </strong>Hyperlipidemic rats were induced using a high-fat diet and randomized according to serum total cholesterol levels using a randomized block design into model, ATV (10 mg/kg), SQ (0.68, 1.68, 3.38 g/kg), and combination groups, and treated for 4 weeks. Serum lipid profiles, liver histopathological changes, pharmacokinetic parameters of ATV, mRNA expression levels of transporters (including Bcrp, Mrp2, etc.) and metabolic enzymes (CYP2C11, CYP3A2), enzyme activities, as well as the effects of SQ's active ingredients were assessed using quantitative PCR, cocktail probe assays, and primary hepatocyte studies.</p><p><strong>Results: </strong>The combination therapy significantly reduced serum lipid levels and improved liver histology, as evidenced by a more organized cellular structure and reduced accumulation of lipid droplets. SQ significantly increased systemic exposure of ATV metabolites, elevating the maximum plasma concentration (C_max) and area under the curve from time 0 to time t (AUC_0-t) of o-ATV by 97.02% and 119.01%, and of p-ATV by 73.22% and 63.39%, respectively (all P<0.05). SQ downregulated the expressions of Bcrp and Mrp2 in the jejunum and Oatp2b1, Bcrp, and Mrp2 in the ileum, while upregulating Oatp1b2 and CYP3A2 in the liver (all P<0.05). Additionally, it enhanced the enzymatic activities of CYP2C11 and CYP3A2, as shown by significantly reduced AUC_0-∞ of omeprazole (P<0.01) and AUC_0-t of midazolam (P<0.05). Notably, tangshenoside I, lobetyolin, and ononin were found to promote CYP3A2 mRNA expression (P<0.05).</p><p><strong>Conclusions: </strong>SQ synergizes with ATV in lipid regulation and hepatoprotection through modulation of drug transporters and metabolic enzymes. These findings suggest that dose adjustment of ATV may be necessary during combination therapy, thereby providing a scientific basis for the rational co-administration of these agents.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Astragaloside IV Mitigates Subarachnoid Hemorrhage-Induced Brain Injury via Regulating Microglial Polarization and Neuroinflammation Mediated by cGAS/STING Pathway.","authors":"Wen-Chao Ding, Yong-Jun Wang, Lu Cao, Wen-Hao Ding, Shu-Qing Yu, Wen-Jing Zheng, Yue-Cheng Cui, Lin-Mei Wang, Shao-Hua Chen, Ning Li, Hao Xu, Qian-Qian Liang, Jin-Man Chen","doi":"10.1007/s11655-026-3954-x","DOIUrl":"https://doi.org/10.1007/s11655-026-3954-x","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of astragaloside IV (AS-IV) on subarachnoid hemorrhage (SAH)-related brain injury and explore the underlying mechanisms.</p><p><strong>Methods: </strong>The effects of related signaling pathways on SAH were analyzed through stimulator of interferon gene (STING) knockout and RNA sequencing (RNA-seq) in mice. In vitro, mouse BV2 microglial cell line was stimulated with hemin to establish a model mimicking SAH. AS-IV was administered after SAH. Neurological deficits and the therapeutic effects of AS-IV in mice were assessed using modified Garcia scores. ELISA and Western blot were employed to measure the expressions of inflammatory factors and the cyclic GMP-AMP synthase (cGAS)/STING signaling pathway both in vivo and in vitro, respectively. TUNEL staining was used to evaluate neuronal apoptosis, Fluoro-Jade C (FJC) staining for neuronal degeneration, immunofluorescence for microglial activation and polarization, and flow cytometry for myeloid cell changes in peripheral blood.</p><p><strong>Results: </strong>The knockout of STING alleviated early brain injury following SAH (P<0.01). RNA-seq revealed the activation of the cGAS/STING and NF-κB related pathways following SAH. In vitro, hemin elevated cGAS-STING and inflammatory factor levels in microglial cells, while AS-IV significantly inhibited these effects (P<0.05 or P<0.01). SAH mice showed reduced neurological scores, obvious systemic inflammation, increased neuronal apoptosis and degeneration, with elevated cGAS-STING pathway and inflammatory factors in brain tissue (P<0.05 or P<0.01). AS-IV suppressed these effects and improved microglial activation and morphology (P<0.05 or P<0.01).</p><p><strong>Conclusions: </strong>In the early stage of brain injury following SAH, AS-IV regulates microglial polarization through the cGAS/STING pathway, thus improving neurological outcomes and alleviating neuroinflammation. AS-IV may be an effective therapeutic agent for the pathology of neuroinflammation following SAH.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Naoxueshu Oral Liquid Promotes Hematoma Absorption and Relieves Neurological Symptoms in Chronic Subdural Hematoma Patients: A Prospective, Single-Arm, Self-Controlled Study.","authors":"Yan-Ping Tong, Li Li, Xiao-Han Zhang, Wei-Ming Liu, Liang Wu, Wei Wei, Tao Yang, Zhi-Hong Li, Hong-You Fan, Yong-Ping Fan","doi":"10.1007/s11655-026-3958-6","DOIUrl":"https://doi.org/10.1007/s11655-026-3958-6","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the potential of Naoxueshu Oral Liquid (NXS) to promote hematoma absorption in patients with chronic subdural hematoma (CSDH).</p><p><strong>Methods: </strong>From September 2020 to August 2023, 60 patients with CSDH confirmed by computed tomography (CT) scan were enrolled in this prospective clinical trial. All patients received NXS at a dose of 10 mL thrice daily for 90 d. The outcomes included changes in maximal hematoma thickness (MHT), scores of Markwalder Grading Scale-Glasgow Coma Scale (MGS-GCS) and Barthel Index (BI) on days 30, 60, 90, and 180 from baseline, as well as the relapse rate by day 180. For subgroup analysis, patients aged over 60 years were divided into an elderly group (60-74 years) and an oldest-old group (> 75 years) to evaluate the effect of NXS in older individuals. Safety was also assessed during the study.</p><p><strong>Results: </strong>All participants were included in the full analysis set (FAS) according to the modified intention-to-treat principle. On day 90, MHT significantly decreased from 16.00 [interquartile range [(IQR) 12.00-24.60] mm to 3.75 (IQR 0-10.00) mm (P<0.01), with complete hematoma absorption observed in 30% (18/60) of patients. MGS-GCS scores on days 90 and 180 and BI on day 180 significantly improved compared with baseline (P<0.05 or P<0.01). The relapse rate on day 180 was 1.5% (1/60) in the FAS. Both subgroups showed significant within-group improvements in MHT, MGS-GCS, and BI (P<0.01). Intergroup differences were noted in MHT, BI, and MGS-GCS at specific time points (P<0.05 or P<0.01). No treatment-related adverse events were reported.</p><p><strong>Conclusions: </strong>NXS may promote hematoma absorption and improve neurological impairment in patients with CSDH. These findings suggest that NXS represents a potentially effective treatment for CSDH. (Trial registration No. ChiCTR2400090565).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Tianma Gouteng Yin in Treating Hypertension-Associated Vascular Cognitive Impairment: Insights from Experiments, Network Pharmacology, and Molecular Docking.","authors":"Na-Chuan Li, Ya-Wei Du, Hong-Xiao Zhang, Fan-Ying Zhao, Liu-Feng Yi, Xiang-Zhao Wang, Zi-Wang Liu","doi":"10.1007/s11655-026-4039-6","DOIUrl":"https://doi.org/10.1007/s11655-026-4039-6","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate active components of Tianma Gouteng Yin (TMGTY) and its mechanisms in treating hypertension-associated vascular cognitive impairment (VCI).</p><p><strong>Methods: </strong>Network pharmacology and molecular docking were used to identify major active ingredients and potential targets of TMGTY in treating hypertension-associated VCI. An in vivo model was established using spontaneously hypertensive rats subjected to unilateral common carotid artery occlusion and a high-salt diet. Rats were randomly divided into 7 groups by a simple randomization method: control, model, sham, low-, medium-, and high-dose TMGTY, and nimodipine groups (n=6). After 28 days of oral administration, blood pressure, behavioral studies, pathological staining, and molecular mechanisms were assessed via tail artery blood pressure monitoring, the morris water maze test, HE staining, immunofluorescence staining, ELISA, and Western blotting.</p><p><strong>Results: </strong>Network analysis identified quercetin, kaempferol, beta-sitosterol, and stigmasterol as key ingredients. Pathway enrichment analysis identified the NF-κB signaling pathway as a key pathway through which TMGTY antagonizes the development of hypertension combined with VCI. Core targets included glyceraldehyde-3-phosphate dehydrogenase (GAPDH), interleukin 6 (IL-6), insulin (INS), tumor necrosis factor (TNF), and tumor protein p53 (TP53), and molecular docking confirmed stable binding to TNF and INS. In vivo experiments demonstrated that TMGTY significantly enhanced cognitive performance and reduced blood pressure. Furthermore, it lowered the levels of pro-inflammatory factors (IL-1β, IL-6, TNF-α, Ang-II) and malondialdehyde (MDA), while elevating superoxide dismutase (SOD) expression (P<0.05 or P<0.01). Immunofluorescence staining further revealed that TMGTY treatment reduced the number of Iba1- and CD16-labeled microglia in the hippocampal CA1 region, thereby alleviating neuroinflammation. Additionally, TMGTY inhibited the expression levels of p-NF-κB p65/NF-κB p65 proteins and attenuated neuroinflammation.</p><p><strong>Conclusion: </strong>TMGTY exerts multi-component, multi-target effects on hypertension-associated VCI, mitigating neuroinflammation and oxidative stress via modulation of NF-κB signaling pathway.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}